APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaginal Fungi Infections Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vaginal Fungi Infections Treatment Market Analysis and Forecast 2026-2032

19 December 2025193 pages

Choose your research edition.

Industry ResearchVaginal Fungi Infections Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginal Fungi Infections Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Vaginal Fungi Infections Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginal Fungi Infections Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginal Fungi Infections Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vaginal Fungi Infections Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Vaginal Fungi Infections Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vaginal Fungi Infections Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vaginal Fungi Infections Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vaginal Fungi Infections Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Vaginal Fungi Infections Treatment include ANI Pharmaceuticals, Aurobindo Pharma Limited, Bausch Health Companies Inc, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals and PEPTONIC medical AB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Vaginal Fungi Infections Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vaginal Fungi Infections Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Vaginal Fungi Infections Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vaginal Fungi Infections Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vaginal Fungi Infections Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Vaginal Fungi Infections Treatment revenue, projected growth trends, production technology, application and end-user industry.

Vaginal Fungi Infections Treatment Segment by Company

ANI Pharmaceuticals

Aurobindo Pharma Limited

Bausch Health Companies Inc

Dr. Reddy's Laboratories

Glenmark Pharmaceuticals Limited

Hikma Pharmaceuticals Plc

Lupin Limited

Mycovia Pharmaceuticals

PEPTONIC medical AB

SCYNEXIS

Unique Pharmaceuticals

Pfizer Inc.

Vaginal Fungi Infections Treatment Segment by Type

Flucytosine

Fluconazole

Nystatin

Others

Vaginal Fungi Infections Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Vaginal Fungi Infections Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginal Fungi Infections Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginal Fungi Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginal Fungi Infections Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Vaginal Fungi Infections Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Vaginal Fungi Infections Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vaginal Fungi Infections Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vaginal Fungi Infections Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Flucytosine Major Player Table 3. Fluconazole Major Player Table 4. Nystatin Major Player Table 5. Others Major Player Table 6. Global Vaginal Fungi Infections Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Player Table 8. Online Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. Vaginal Fungi Infections Treatment Industry Trends Table 11. Vaginal Fungi Infections Treatment Industry Drivers Table 12. Vaginal Fungi Infections Treatment Industry Opportunities and Challenges Table 13. Vaginal Fungi Infections Treatment Industry Restraints Table 14. Global Vaginal Fungi Infections Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Vaginal Fungi Infections Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Vaginal Fungi Infections Treatment Market Share by Region (2021-2026) Table 17. Global Vaginal Fungi Infections Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Vaginal Fungi Infections Treatment Market Share by Region (2027-2032) Table 19. Global Vaginal Fungi Infections Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Vaginal Fungi Infections Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Vaginal Fungi Infections Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Vaginal Fungi Infections Treatment Key Players Headquarters & Area Served Table 23. Global Vaginal Fungi Infections Treatment Players, Product Type & Application Table 24. Global Vaginal Fungi Infections Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Vaginal Fungi Infections Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Vaginal Fungi Infections Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Vaginal Fungi Infections Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Vaginal Fungi Infections Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Vaginal Fungi Infections Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Vaginal Fungi Infections Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Vaginal Fungi Infections Treatment Revenue Market Share by Application (2027-2032) Table 37. ANI Pharmaceuticals Company Information Table 38. ANI Pharmaceuticals Business Overview Table 39. ANI Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. ANI Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 41. ANI Pharmaceuticals Recent Development Table 42. Aurobindo Pharma Limited Company Information Table 43. Aurobindo Pharma Limited Business Overview Table 44. Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Product Portfolio Table 46. Aurobindo Pharma Limited Recent Development Table 47. Bausch Health Companies Inc Company Information Table 48. Bausch Health Companies Inc Business Overview Table 49. Bausch Health Companies Inc Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Bausch Health Companies Inc Vaginal Fungi Infections Treatment Product Portfolio Table 51. Bausch Health Companies Inc Recent Development Table 52. Dr. Reddy's Laboratories Company Information Table 53. Dr. Reddy's Laboratories Business Overview Table 54. Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Product Portfolio Table 56. Dr. Reddy's Laboratories Recent Development Table 57. Glenmark Pharmaceuticals Limited Company Information Table 58. Glenmark Pharmaceuticals Limited Business Overview Table 59. Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Product Portfolio Table 61. Glenmark Pharmaceuticals Limited Recent Development Table 62. Hikma Pharmaceuticals Plc Company Information Table 63. Hikma Pharmaceuticals Plc Business Overview Table 64. Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Product Portfolio Table 66. Hikma Pharmaceuticals Plc Recent Development Table 67. Lupin Limited Company Information Table 68. Lupin Limited Business Overview Table 69. Lupin Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Lupin Limited Vaginal Fungi Infections Treatment Product Portfolio Table 71. Lupin Limited Recent Development Table 72. Mycovia Pharmaceuticals Company Information Table 73. Mycovia Pharmaceuticals Business Overview Table 74. Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 76. Mycovia Pharmaceuticals Recent Development Table 77. PEPTONIC medical AB Company Information Table 78. PEPTONIC medical AB Business Overview Table 79. PEPTONIC medical AB Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. PEPTONIC medical AB Vaginal Fungi Infections Treatment Product Portfolio Table 81. PEPTONIC medical AB Recent Development Table 82. SCYNEXIS Company Information Table 83. SCYNEXIS Business Overview Table 84. SCYNEXIS Vaginal Fungi Infections Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. SCYNEXIS Vaginal Fungi Infections Treatment Product Portfolio Table 86. SCYNEXIS Recent Development Table 87. Unique Pharmaceuticals Company Information Table 88. Unique Pharmaceuticals Business Overview Table 89. Unique Pharmaceuticals Vaginal Fungi Infections Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Unique Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio Table 91. Unique Pharmaceuticals Recent Development Table 92. Pfizer Inc. Company Information Table 93. Pfizer Inc. Business Overview Table 94. Pfizer Inc. Vaginal Fungi Infections Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pfizer Inc. Vaginal Fungi Infections Treatment Product Portfolio Table 96. Pfizer Inc. Recent Development Table 97. North America Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Vaginal Fungi Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 103. North America Vaginal Fungi Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 104. Europe Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Vaginal Fungi Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 110. Europe Vaginal Fungi Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 111. China Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 112. China Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 113. China Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 114. China Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 116. Asia Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 117. Asia Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 118. Asia Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Vaginal Fungi Infections Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Vaginal Fungi Infections Treatment Revenue by Region (US$ Million) & (2021-2026) Table 121. Asia Vaginal Fungi Infections Treatment Revenue by Region (US$ Million) & (2027-2032) Table 122. SAMEA Vaginal Fungi Infections Treatment Revenue by Type (2021-2026) & (US$ Million) Table 123. SAMEA Vaginal Fungi Infections Treatment Revenue by Type (2027-2032) & (US$ Million) Table 124. SAMEA Vaginal Fungi Infections Treatment Revenue by Application (2021-2026) & (US$ Million) Table 125. SAMEA Vaginal Fungi Infections Treatment Revenue by Application (2027-2032) & (US$ Million) Table 126. SAMEA Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. SAMEA Vaginal Fungi Infections Treatment Revenue by Country (2021-2026) & (US$ Million) Table 128. SAMEA Vaginal Fungi Infections Treatment Revenue by Country (US$ Million) & (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Vaginal Fungi Infections Treatment Image Figure 2. Global Vaginal Fungi Infections Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaginal Fungi Infections Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Flucytosine Image Figure 5. Fluconazole Image Figure 6. Nystatin Image Figure 7. Others Image Figure 8. Global Vaginal Fungi Infections Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Vaginal Fungi Infections Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Vaginal Fungi Infections Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Vaginal Fungi Infections Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Vaginal Fungi Infections Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Vaginal Fungi Infections Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Vaginal Fungi Infections Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Vaginal Fungi Infections Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Vaginal Fungi Infections Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Vaginal Fungi Infections Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Vaginal Fungi Infections Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Vaginal Fungi Infections Treatment Revenue Market Share by Application (2021-2032) Figure 24. North America Vaginal Fungi Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032) Figure 26. North America Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032) Figure 27. North America Vaginal Fungi Infections Treatment Revenue Share by Country (2021-2032) Figure 28. United States Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Vaginal Fungi Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Vaginal Fungi Infections Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Vaginal Fungi Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032) Figure 45. China Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Vaginal Fungi Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Vaginal Fungi Infections Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Vaginal Fungi Infections Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Vaginal Fungi Infections Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Vaginal Fungi Infections Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Flucytosine
  • Fluconazole
  • Nystatin
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • ANI Pharmaceuticals
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc
  • Dr. Reddy's Laboratories
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals
  • PEPTONIC medical AB
  • SCYNEXIS
  • Unique Pharmaceuticals
  • Pfizer Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vaginal Fungi Infections Treatment Market by Type
  3. 1.2.1 Global Vaginal Fungi Infections Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Flucytosine
  5. 1.2.3 Fluconazole
  6. 1.2.4 Nystatin
  7. 1.2.5 Others
  8. 1.3 Vaginal Fungi Infections Treatment Market by Application
  9. 1.3.1 Global Vaginal Fungi Infections Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Vaginal Fungi Infections Treatment Market Dynamics
  1. 2.1 Vaginal Fungi Infections Treatment Industry Trends
  2. 2.2 Vaginal Fungi Infections Treatment Industry Drivers
  3. 2.3 Vaginal Fungi Infections Treatment Industry Opportunities and Challenges
  4. 2.4 Vaginal Fungi Infections Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Vaginal Fungi Infections Treatment Market Perspective (2021-2032)
  2. 3.2 Global Vaginal Fungi Infections Treatment Growth Trends by Region
  3. 3.2.1 Global Vaginal Fungi Infections Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vaginal Fungi Infections Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Vaginal Fungi Infections Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Vaginal Fungi Infections Treatment Revenue by Players
  2. 4.1.1 Global Vaginal Fungi Infections Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Vaginal Fungi Infections Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Vaginal Fungi Infections Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vaginal Fungi Infections Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Vaginal Fungi Infections Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Vaginal Fungi Infections Treatment Players, Product Type & Application
  8. 4.5 Global Vaginal Fungi Infections Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Vaginal Fungi Infections Treatment Market CR5 and HHI
  11. 4.6.3 2025 Vaginal Fungi Infections Treatment Tier 1, Tier 2, and Tier 3
5 Vaginal Fungi Infections Treatment Market Size by Type
  1. 5.1 Global Vaginal Fungi Infections Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Vaginal Fungi Infections Treatment Revenue Market Share by Type (2021-2032)
6 Vaginal Fungi Infections Treatment Market Size by Application
  1. 6.1 Global Vaginal Fungi Infections Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Vaginal Fungi Infections Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ANI Pharmaceuticals
  2. 7.1.1 ANI Pharmaceuticals Company Information
  3. 7.1.2 ANI Pharmaceuticals Business Overview
  4. 7.1.3 ANI Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ANI Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  6. 7.1.5 ANI Pharmaceuticals Recent Developments
  7. 7.2 Aurobindo Pharma Limited
  8. 7.2.1 Aurobindo Pharma Limited Company Information
  9. 7.2.2 Aurobindo Pharma Limited Business Overview
  10. 7.2.3 Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Aurobindo Pharma Limited Vaginal Fungi Infections Treatment Product Portfolio
  12. 7.2.5 Aurobindo Pharma Limited Recent Developments
  13. 7.3 Bausch Health Companies Inc
  14. 7.3.1 Bausch Health Companies Inc Company Information
  15. 7.3.2 Bausch Health Companies Inc Business Overview
  16. 7.3.3 Bausch Health Companies Inc Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bausch Health Companies Inc Vaginal Fungi Infections Treatment Product Portfolio
  18. 7.3.5 Bausch Health Companies Inc Recent Developments
  19. 7.4 Dr. Reddy's Laboratories
  20. 7.4.1 Dr. Reddy's Laboratories Company Information
  21. 7.4.2 Dr. Reddy's Laboratories Business Overview
  22. 7.4.3 Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dr. Reddy's Laboratories Vaginal Fungi Infections Treatment Product Portfolio
  24. 7.4.5 Dr. Reddy's Laboratories Recent Developments
  25. 7.5 Glenmark Pharmaceuticals Limited
  26. 7.5.1 Glenmark Pharmaceuticals Limited Company Information
  27. 7.5.2 Glenmark Pharmaceuticals Limited Business Overview
  28. 7.5.3 Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Glenmark Pharmaceuticals Limited Vaginal Fungi Infections Treatment Product Portfolio
  30. 7.5.5 Glenmark Pharmaceuticals Limited Recent Developments
  31. 7.6 Hikma Pharmaceuticals Plc
  32. 7.6.1 Hikma Pharmaceuticals Plc Company Information
  33. 7.6.2 Hikma Pharmaceuticals Plc Business Overview
  34. 7.6.3 Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Hikma Pharmaceuticals Plc Vaginal Fungi Infections Treatment Product Portfolio
  36. 7.6.5 Hikma Pharmaceuticals Plc Recent Developments
  37. 7.7 Lupin Limited
  38. 7.7.1 Lupin Limited Company Information
  39. 7.7.2 Lupin Limited Business Overview
  40. 7.7.3 Lupin Limited Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lupin Limited Vaginal Fungi Infections Treatment Product Portfolio
  42. 7.7.5 Lupin Limited Recent Developments
  43. 7.8 Mycovia Pharmaceuticals
  44. 7.8.1 Mycovia Pharmaceuticals Company Information
  45. 7.8.2 Mycovia Pharmaceuticals Business Overview
  46. 7.8.3 Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Mycovia Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  48. 7.8.5 Mycovia Pharmaceuticals Recent Developments
  49. 7.9 PEPTONIC medical AB
  50. 7.9.1 PEPTONIC medical AB Company Information
  51. 7.9.2 PEPTONIC medical AB Business Overview
  52. 7.9.3 PEPTONIC medical AB Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 PEPTONIC medical AB Vaginal Fungi Infections Treatment Product Portfolio
  54. 7.9.5 PEPTONIC medical AB Recent Developments
  55. 7.10 SCYNEXIS
  56. 7.10.1 SCYNEXIS Company Information
  57. 7.10.2 SCYNEXIS Business Overview
  58. 7.10.3 SCYNEXIS Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 SCYNEXIS Vaginal Fungi Infections Treatment Product Portfolio
  60. 7.10.5 SCYNEXIS Recent Developments
  61. 7.11 Unique Pharmaceuticals
  62. 7.11.1 Unique Pharmaceuticals Company Information
  63. 7.11.2 Unique Pharmaceuticals Business Overview
  64. 7.11.3 Unique Pharmaceuticals Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Unique Pharmaceuticals Vaginal Fungi Infections Treatment Product Portfolio
  66. 7.11.5 Unique Pharmaceuticals Recent Developments
  67. 7.12 Pfizer Inc.
  68. 7.12.1 Pfizer Inc. Company Information
  69. 7.12.2 Pfizer Inc. Business Overview
  70. 7.12.3 Pfizer Inc. Vaginal Fungi Infections Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Pfizer Inc. Vaginal Fungi Infections Treatment Product Portfolio
  72. 7.12.5 Pfizer Inc. Recent Developments
8 North America
  1. 8.1 North America Vaginal Fungi Infections Treatment Revenue (2021-2032)
  2. 8.2 North America Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Vaginal Fungi Infections Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Vaginal Fungi Infections Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Vaginal Fungi Infections Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Vaginal Fungi Infections Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Vaginal Fungi Infections Treatment Revenue by Country
  11. 8.6.1 North America Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Vaginal Fungi Infections Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Vaginal Fungi Infections Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Vaginal Fungi Infections Treatment Revenue (2021-2032)
  2. 9.2 Europe Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Vaginal Fungi Infections Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Vaginal Fungi Infections Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Vaginal Fungi Infections Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Vaginal Fungi Infections Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Vaginal Fungi Infections Treatment Revenue by Country
  11. 9.6.1 Europe Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Vaginal Fungi Infections Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Vaginal Fungi Infections Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Vaginal Fungi Infections Treatment Revenue (2021-2032)
  2. 10.2 China Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Vaginal Fungi Infections Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Vaginal Fungi Infections Treatment Revenue by Type (2027-2032)
  5. 10.3 China Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Vaginal Fungi Infections Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Vaginal Fungi Infections Treatment Revenue by Application (2027-2032)
  9. 10.5 China Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vaginal Fungi Infections Treatment Revenue (2021-2032)
  2. 11.2 Asia Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Vaginal Fungi Infections Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Vaginal Fungi Infections Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Vaginal Fungi Infections Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Vaginal Fungi Infections Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Vaginal Fungi Infections Treatment Revenue by Country
  11. 11.6.1 Asia Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Vaginal Fungi Infections Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Vaginal Fungi Infections Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vaginal Fungi Infections Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Vaginal Fungi Infections Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Vaginal Fungi Infections Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Vaginal Fungi Infections Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Vaginal Fungi Infections Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Vaginal Fungi Infections Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Vaginal Fungi Infections Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Vaginal Fungi Infections Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Vaginal Fungi Infections Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Vaginal Fungi Infections Treatment Revenue by Country
  11. 12.6.1 SAMEA Vaginal Fungi Infections Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Vaginal Fungi Infections Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Vaginal Fungi Infections Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst